3 Monster Stocks in the Making to Buy Right Now
What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be monster stocks in the making. Here's why these chose Axsome Therapeutics (NASDAQ: AXSM), CRISPR Therapeutics (NASDAQ: CRSP), and Intellia Therapeutics (NASDAQ: NTLA).
Keith Speights (Axsome Therapeutics): Right now, Axsome Therapeutics' market capitalization stands below $4 billion. But the company has multiple arrows in its quiver. I expect that Axsome will grow much larger if only a few of them hit their mark.
Axsome already has two approved products. Auvelity won U.S. Food and Drug Administration (FDA) approval in August 2022 as a treatment for major depressive disorder (MDD). Axsome also acquired sleep-disorder drug Sunosi from Jazz Pharmaceuticals last year.
Source Fool.com
Axsome Therapeutics Inc Aktie
Die Axsome Therapeutics Inc Aktie hat zu wenige Einschätzungen, um eine Tendenz festzustellen.
Ein Kursziel von 100 € für Axsome Therapeutics Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 84.04 €.